2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2006101162v1 18/6/1721    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pawar, R. D. Articles by Anders, H.-J. Search for Related Content PubMed PubMed Citation Articles by Pawar, R. D. Articles by Anders, H.-J.

Inhibition of Toll-Like Receptor-7 (TLR-7) or TLR-7 plus TLR-9 Attenuates Glomerulonephritis and Lung Injury in Experimental Lupus

Medical Policlinic, Ludwig-Maximilians-University, Munich, Germany

Address correspondence to: Dr. Hans-Joachim Anders, Medizinische Poliklinik, University of Munich, Pettenkoferstrasse 8a, 80336 Munich, Germany. Phone: +49-89-218075846; Fax: +49-89-218075860; E-mail: hjanders{at}med.uni-muenchen.de

Received for publication October 27, 2006. Accepted for publication March 18, 2007.

Small nuclear RNA and associated lupus autoantigens activate B cells and dendritic cells via Toll-like receptor-7 (TLR-7); therefore, TLR-7 may represent a potential therapeutic target in lupus. MRL lpr mice were administered an injection of either saline or synthetic oligodeoxynucleotides with immunoregulatory sequences (IRS) that specifically block signaling via TLR-7 (IRS 661) or via TLR-7 and TLR-9 (IRS 954, which uses a active sequence from IRS 661 along with a TLR-9 inhibitory sequence) from weeks 11 to 24 of age. IRS 661 and IRS 954 both significantly reduced the weight of spleen and lymph nodes as well as serum levels of TNF as compared with saline-treated MRL lpr mice. Only IRS 661 but not IRS 954 significantly reduced serum levels of IL-12p40, anti-dsDNA IgG_2a, IgG_2b, and anti-Smith IgG. Both IRS localized to the kidney after intraperitoneal injection and significantly improved the activity index and chronicity index for lupus nephritis in MRL lpr mice. This was associated with significant reduction of renal glomerular and interstitial macrophage infiltrates and the number of interstitial T cells. Autoimmune lung injury was also attenuated with IRS 661 and IRS 954. These data demonstrate that TLR-7 antagonism, initiated after the onset of autoimmunity, can prevent autoimmune kidney and lung injury in MRL lpr mice. Concomitant blockade of TLR-9 with IRS 954 neutralized the effect of TLR-7 blockade on dsDNA IgG_2a, dsDNA IgG_2b, and Smith antigen autoantibodies but had neither additive nor opposing effects on autoimmune lung and kidney injury. Hence, TLR-7 is proposed as a novel and potential therapeutic target in systemic lupus erythematosus.

This article has been cited by other articles:

				M. Lech, O. P. Kulkarni, S. Pfeiffer, E. Savarese, A. Krug, C. Garlanda, A. Mantovani, and H.-J. Anders Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens J. Exp. Med., August 4, 2008; 205(8): 1879 - 1888. [Abstract] [Full Text] [PDF]

				A. C. Shirali and D. R. Goldstein Tracking the Toll of Kidney Disease J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1444 - 1450. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673